Literature DB >> 9884085

Involvement of 5-HT6 receptors in nigro-striatal function in rodents.

A Bourson1, F G Boess, M Bös, A J Sleight.   

Abstract

4-Amino-N-(2,4 bis-methylamino-pyrimidin-4-yl) benzene sulphonamide (Ro 04-6790) is a potent, selective and competitive antagonist for the 5-HT6 receptor which can be detected in the cerebro-spinal fluid (CSF) of rats following intraperitoneal administration. Since 5-HT6 receptor mRNA and 5-HT6 receptor-like immunoreactivity have been shown to be present in the striatum, the purpose of the present study was to evaluate the effect of 5-HT6 receptor antagonism on haloperidol- and SCH 23390-induced catalepsy in mice and on the turning behaviour of rats with unilateral 6-hydroxydopamine (6-OHDA) lesions of the medial forebrain bundle. Ro 04-6790 (3, 10 and 30 mg kg(-1) i.p.) did not induce catalepsy and had no effect on catalepsy induced by either haloperidol or SCH 23390. Ro 04-6790 (3, 10 and 30 mg kg(-1) i.p.) did not itself induce rotational behaviour in rats with unilateral 6-hydroxydopamine (6-OHDA) lesions of the medial forebrain bundle nor did it affect the rotational behaviour induced by either L-Dopa or amphetamine. 5-HT6 receptor antagonism inhibited the rotational behaviour of 6-OHDA lesioned rats induced by treatment with the muscarinic antagonists scopolamine and atropine. The data support earlier conclusions from experiments with antisense oligonucleotides that the 5-HT6 receptor is involved in the control of acetylcholine neurotransmission in the rat brain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9884085      PMCID: PMC1565738          DOI: 10.1038/sj.bjp.0702230

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist.

Authors:  C Routledge; S M Bromidge; S F Moss; G W Price; W Hirst; H Newman; G Riley; T Gager; T Stean; N Upton; S E Clarke; A M Brown; D N Middlemiss
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  Biodistribution and radiation dosimetry of the serotonin 5-HT₆ ligand [¹¹C]GSK215083 determined from human whole-body PET.

Authors:  Robert A Comley; Cristian Salinas; Romina Mizrahi; Irina Vitcu; Alvina Ng; William Hallett; Nicholas Keat; Alan A Wilson; Eugenii A Rabiner; Marc Laruelle; Sylvain Houle
Journal:  Mol Imaging Biol       Date:  2012-08       Impact factor: 3.488

3.  Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.

Authors:  Marieke Liem-Moolenaar; Mandana Rad; Stefano Zamuner; Adam F Cohen; Francesca Lemme; Kari L Franson; Joop M A van Gerven; Emilio Merlo Pich
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

4.  5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats.

Authors:  Paula D Hatcher; Verity J Brown; David S Tait; Simon Bate; Philip Overend; Jim J Hagan; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

5.  In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate.

Authors:  L A Dawson; H Q Nguyen; P Li
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

6.  Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue.

Authors:  W D Hirst; J A Minton; S M Bromidge; S F Moss; A J Latter; G Riley; C Routledge; D N Middlemiss; G W Price
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

7.  Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.

Authors:  Mark J Millan; Sylvie Veiga; Sylvie Girardon; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

Review 8.  Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.

Authors:  Bryan L Roth; S Mohammad Hanizavareh; Andrew E Blum
Journal:  Psychopharmacology (Berl)       Date:  2003-12-02       Impact factor: 4.530

9.  Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790.

Authors:  Marie L Woolley; Charles A Marsden; Andrew J Sleight; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

10.  Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.

Authors:  Michael Riedel; Norbert Müller; Ilja Spellmann; Rolf R Engel; Richard Musil; Rosamaria Valdevit; Sandra Dehning; Anette Douhet; Anja Cerovecki; Martin Strassnig; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-10       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.